Drug that delays spread of prostate cancer

18 Nov 2018

The study made by German drug maker Bayer and Finland’s Orion resulted in a drug that can slow down the spread of prostate cancer to other body parts. The companies stated that the study on men with non-metastatic prostate cancer was not showing any result or development by hormonal therapy and that set the main goal of oral drug darolutamide by delaying the speed. The U.S. Food and Drug Administration has granted the “fast track” designation to darolutamide which would speed up the marketing approval required from the health authorities.

The Ultimate Pharma Guide

©2018 Copyright. All rights reserved. Powered by . Designed by Hats-Off

Log in with your credentials

Forgot your details?